Treatment Details – 13.0 months
|Patients: This phase I to II study involved 61 patients with mesothelioma, 44 of which received the combination (surgery and chemotherapy) treatment. These patients had a median age of 71 years, ranging from 50 to 82 years and 73% were male.|
Treatment: 44 patients had surgery (macroscopic complete resection) followed by treatment with the chemotherapy drug cisplatin by lavage.
Toxicity: 10 patients had a grade 5 toxicity (death) from major morbidity of grade 3+, respiratory failure/adult respiratory distress syndrome, and multi-organ failure. Grade 3 and 4 toxicities included atrial fibrillation, deep vein thrombosis, technical complications, respiratory failure/adult respiratory distress syndrome, pneumonia and renal toxicity.
Results: The median survival time of all 61 registered patients was 9.3 months; those that had surgical resection and cisplatin had a median survival time of 13 months. Among these patients, 35 were given a higher dose of cisplatin and had a median survival of 18 months, and 7 were still alive 30-50 months after the surgery. Those given a lower dose had a median survival time of 6 months (and all died within 15 months).
Correspondence: David Sugarbaker, M.D.